Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449’s Potential as a New Treatment for Drug-Resistant NSCLC

SUZHOU, China and ROCKVILLE, Md., June 6, 2023 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that for the second consecutive year, it has…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.